Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans, 14860-14862 [2016-06128]
Download as PDF
14860
Federal Register / Vol. 81, No. 53 / Friday, March 18, 2016 / Notices
and preserving the identity, strength,
quality, and purity of the new animal
drug and, in the case of a generic drug,
to ensure that it is equivalent to the
reference listed new animal drug
(RLNAD).
In order to improve the process for
submission and review of CMC
information for animal drugs, CVM has
developed draft GFI #234 entitled
‘‘Question-Based Review for the
Chemistry, Manufacturing, and Controls
Technical Section of Animal Drug
Applications.’’ This guidance contains a
series of questions that focus on the
critical scientific and regulatory issues
and pharmaceutical attributes essential
for ensuring the quality of new animal
drug substances and products. Termed
QbR, these questions provide a general
framework for original CMC
submissions to INAD and JINAD files,
NADAs, ANADAs, CNADAs, and VMFs.
Dated: March 14, 2016.
Leslie Kux,
Associate Commissioner for Policy.
II. Significance of Guidance
ACTION:
This level 1 draft guidance is being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, will represent the current
thinking of FDA on ‘‘Question-Based
Review for the Chemistry,
Manufacturing, and Controls Technical
Section of Animal Drug Applications.’’
It does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
SUMMARY:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
III. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR part 514 have
been approved under OMB control
number 0910–0032; the collections of
information in section 512(n)(1) of the
FD&C Act (21 U.S.C. 360b(n)(1)) have
been approved under OMB control
number 0910–0669.
IV. Electronic Access
Persons with access to the Internet
may obtain the draft guidance at either
https://www.fda.gov/AnimalVeterinary/
GuidanceComplianceEnforcement/
GuidanceforIndustry/default.htm or
https://www.regulations.gov.
VerDate Sep<11>2014
19:50 Mar 17, 2016
Jkt 238001
[FR Doc. 2016–06119 Filed 3–17–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0663]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Investigational
New Drug Safety Reporting
Requirements for Human Drug and
Biological Products and Safety
Reporting Requirements for
Bioavailability and Bioequivalence
Studies in Humans
AGENCY:
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
Investigational New Drug Safety
Reporting Requirements for Human
Drug and Biological Products and Safety
Reporting Requirements for
Bioavailability and Bioequivalence
Studies in Humans.
DATES: Submit either electronic or
written comments on the collection of
information by May 17, 2016.
ADDRESSES: You may submit comments
as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–N–0663 for ‘‘Investigational New
Drug Safety Reporting Requirements for
Human Drug and Biological Products
and Safety Reporting Requirements for
Bioavailability and Bioequivalence
Studies in Humans.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION’’. The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
E:\FR\FM\18MRN1.SGM
18MRN1
14861
Federal Register / Vol. 81, No. 53 / Friday, March 18, 2016 / Notices
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Investigational New Drug Safety
Reporting Requirements for Human
Drug and Biological Products and
Safety Reporting Requirements for
Bioavailability and Bioequivalence
Studies in Humans, OMB Control
Number 0910–0672—Extension
In the Federal Register of October 31,
2013 (78 FR 65338), FDA published a
document entitled ‘‘Investigational New
Drug Safety Reporting Requirements for
Human Drug and Biological Products
and Safety Reporting Requirements for
Bioavailability and Bioequivalence
Studies in Humans.’’ The document
clarified the Agency’s expectations for
timely review, evaluation, and
submission of relevant and useful safety
information and implemented
internationally harmonized definitions
and reporting standards for IND safety
reports. The document also required
safety reporting for bioavailability and
bioequivalence studies. The document
was intended to improve the utility of
Investigational New Drug (IND) safety
reports, expedite FDA’s review of
critical safety information, better protect
human subjects enrolled in clinical
trials, and harmonize safety reporting
requirements internationally.
The rulemaking included the
following information collection under
the PRA that was not already included
in 21 CFR 312.32 and approved under
OMB control number 0910–0014.
Section 312.32(c)(1)(ii) and (c)(1)(iii)
requires reporting to FDA, in an IND
safety report, of potential serious risks
from clinical trials within 15 calendar
days for findings from epidemiological
studies, pooled analyses of multiple
studies, or other clinical studies that
suggest a significant risk in humans
exposed to the drug.
Section 312.32(c)(1)(iii) specifies the
requirements for reporting to FDA in an
IND safety report potential serious risks
from clinical trials within 15 calendar
days for findings from in vitro testing
that suggest a significant risk to humans.
Section 312.32(c)(1)(iv) requires
reporting to FDA in an IND safety report
within 15 calendar days of any
clinically important increase in the rate
of occurrence of serious suspected
adverse reactions over that listed in the
protocol or investigator brochure.
The rulemaking also included new
information collection under the PRA
by requiring safety reporting for
bioavailability and bioequivalence
studies (21 CFR 320.31(d)).
In tables 1 and 2 of this document, the
estimates for ‘‘No. of Respondents,’’
‘‘No. of Responses per Respondent,’’
and ‘‘Total Annual Responses’’ were
obtained from the Center for Drug
Evaluation and Research (CDER) and the
Center for Biologics Evaluation and
Research (CBER) reports and data
management systems for submissions
received in 2013, 2014, and 2015, and
from other sources familiar with the
number of submissions received under
the noted 21 CFR section. The estimates
for ‘‘Hours per Response’’ are
unchanged based on information from
CDER and CBER individuals familiar
with the burden associated with these
reports and from prior estimates
received from the pharmaceutical
industry. FDA estimates the burden of
this collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN—(CDER) 1
Number of
respondents
asabaliauskas on DSK3SPTVN1PROD with NOTICES
21 CFR section
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total hours
320.31(d) Bioavailability and Bioequivalence Safety Reports ..................................................................................
312.32(c)(1)(ii) and (c)(1)(iii) IND Safety Reports ...............
312.32(c)(1)(iv) IND Safety Reports ....................................
13
100
10
15
6
1
195
600
10
14
12
12
2,730
7,200
120
Total (CDER) ................................................................
........................
........................
........................
........................
10,050
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
19:50 Mar 17, 2016
Jkt 238001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
E:\FR\FM\18MRN1.SGM
18MRN1
14862
Federal Register / Vol. 81, No. 53 / Friday, March 18, 2016 / Notices
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN—(CBER) 1
Number of
respondents
21 CFR section
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total hours
320.31(d) Bioavailability and Bioequivalence Safety Reports ..................................................................................
312.32(c)(1)(ii) and (c)(1)(iii) IND Safety Reports ...............
312.32(c)(1)(iv) IND Safety Reports ....................................
1
137
5
1
4
1.4
1
548
7
14
12
12
14
6,576
84
Total (CBER) ................................................................
........................
........................
........................
........................
6,674
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: March 14, 2016.
Leslie Kux,
Associate Commissioner for Policy.
Enforcement, Office of Enforcement and
Import Operations, Office of Regulatory
Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD
20857, 301–796–4640.
[FR Doc. 2016–06128 Filed 3–17–16; 8:45 am]
BILLING CODE 4164–01–P
SUPPLEMENTARY INFORMATION:
I. Background
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–3225]
Wesley A. McQuerry: Debarment Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The U.S. Food and Drug
Administration (FDA or Agency) is
issuing an order under the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) permanently debarring
Wesley A. McQuerry from providing
services in any capacity to a person that
has an approved or pending drug
product application. FDA bases this
order on a finding that Mr. McQuerry
was convicted of a felony under Federal
law for conduct relating to the
development or approval, including the
process for development or approval, of
a drug product and otherwise relating to
the regulation of a drug product under
the FD&C Act. Mr. McQuerry was given
notice of the proposed permanent
debarment and an opportunity to
request a hearing within the timeframe
prescribed by regulation. Mr. McQuerry
failed to respond. Mr. McQuerry’s
failure to respond constitutes a waiver
of his right to a hearing concerning this
action.
DATES: This order is effective March 18,
2016.
ADDRESSES: Submit applications for
special termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Kenny Shade, (ELEM–4144), Division of
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:50 Mar 17, 2016
Jkt 238001
Section 306(a)(2)(A) of the FD&C Act
(21 U.S.C. 335a(a)(2)(A)) requires
debarment of an individual if FDA finds
that the individual has been convicted
of a felony under Federal law for
conduct relating to the development or
approval, including the process for
development or approval, of any drug
product. Section 306(a)(2)(B) of the
FD&C Act requires debarment of an
individual if FDA finds that the
individual has been convicted of a
felony under Federal law for conduct
otherwise relating to the regulation of
any drug product under the FD&C Act.
On February 10, 2015, the U.S. District
Court for the Northern District of Illinois
entered judgment against Mr. McQuerry
for one count of falsifying a material
fact, in violation of 18 U.S.C. 1001(a)(1).
The factual basis for this conviction is
as follows: Mr. McQuerry was the study
coordinator for a drug clinical trial at an
institution in the Northern District of
Illinois. The clinical trial occurred
under the authority of FDA, and clinical
trial data was required to be submitted
to FDA before the drug could be
approved for sale in the United States.
As study coordinator, Mr. McQuerry’s
responsibilities for administering the
clinical trial included, among other
things, coordinating patient visits,
maintaining patient files, ensuring that
administrative procedures were
followed regarding the collection of
patient data, disbursing American
Express gift checks to trial participants,
and transmitting clinical trial data from
the institution to the administrator,
which was administering the clinical
trial on behalf of the pharmaceutical
company. Mr. McQuerry knew that the
results of the clinical trial would be
reported to FDA, and he knew it was
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
unlawful to provide false information to
the pharmaceutical company.
Beginning no later than January 2008,
and continuing through at least October
2008, in the Northern District of Illinois,
Mr. McQuerry knowingly and willfully
falsified, concealed, and covered up by
trick, scheme, and device material facts
in a matter within the jurisdiction of
FDA, namely that at least four patients
and others were participating in the
drug clinical trial, when in fact these
patients did not participate in that
clinical trial. Specifically, between
January and October 2008, Mr.
McQuerry created fifteen to twenty
fictional patients, whom he claimed
were participants in the clinical trial.
Mr. McQuerry falsified signatures of
those patients on consent forms and
falsified doctors’ signatures on medical
evaluations for those patients. He
provided his own blood, stool, and EKG
results, which he claimed were
provided by the fictional patients. He
also transmitted false data and
information to the administrator
regarding these fictional patients and
made and caused to be made false
statements regarding their participation
in the study and attendance at office
visits, all of which he knew would be
provided to the pharmaceutical
company and to FDA.
Mr. McQuerry made false statements
to the administrator about the
whereabouts of the fictitious trial
participants. In particular, on August
28, 2008, he provided false and
fraudulent statements to the
administrator regarding the attendance
of two patients at study visits, knowing
that the two patients were not in fact
enrolled in the study and did not attend
a single study visit.
As study coordinator, Mr. McQuerry
was responsible for disbursing gift
checks, which were provided by the
pharmaceutical company to patients at
various points during the patients’
participation in the clinical trial. Mr.
McQuerry falsely and fraudulently
claimed to have disbursed gift checks
when, in fact, no checks were disbursed
E:\FR\FM\18MRN1.SGM
18MRN1
Agencies
[Federal Register Volume 81, Number 53 (Friday, March 18, 2016)]
[Notices]
[Pages 14860-14862]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-06128]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0663]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Investigational New Drug Safety Reporting Requirements
for Human Drug and Biological Products and Safety Reporting
Requirements for Bioavailability and Bioequivalence Studies in Humans
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on Investigational New Drug
Safety Reporting Requirements for Human Drug and Biological Products
and Safety Reporting Requirements for Bioavailability and
Bioequivalence Studies in Humans.
DATES: Submit either electronic or written comments on the collection
of information by May 17, 2016.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-N-0663 for ``Investigational New Drug Safety Reporting
Requirements for Human Drug and Biological Products and Safety
Reporting Requirements for Bioavailability and Bioequivalence Studies
in Humans.'' Received comments will be placed in the docket and, except
for those submitted as ``Confidential Submissions,'' publicly viewable
at https://www.regulations.gov or at the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION''. The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be
[[Page 14861]]
made publicly available, you can provide this information on the cover
sheet and not in the body of your comments and you must identify this
information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Investigational New Drug Safety Reporting Requirements for Human Drug
and Biological Products and Safety Reporting Requirements for
Bioavailability and Bioequivalence Studies in Humans, OMB Control
Number 0910-0672--Extension
In the Federal Register of October 31, 2013 (78 FR 65338), FDA
published a document entitled ``Investigational New Drug Safety
Reporting Requirements for Human Drug and Biological Products and
Safety Reporting Requirements for Bioavailability and Bioequivalence
Studies in Humans.'' The document clarified the Agency's expectations
for timely review, evaluation, and submission of relevant and useful
safety information and implemented internationally harmonized
definitions and reporting standards for IND safety reports. The
document also required safety reporting for bioavailability and
bioequivalence studies. The document was intended to improve the
utility of Investigational New Drug (IND) safety reports, expedite
FDA's review of critical safety information, better protect human
subjects enrolled in clinical trials, and harmonize safety reporting
requirements internationally.
The rulemaking included the following information collection under
the PRA that was not already included in 21 CFR 312.32 and approved
under OMB control number 0910-0014.
Section 312.32(c)(1)(ii) and (c)(1)(iii) requires reporting to FDA,
in an IND safety report, of potential serious risks from clinical
trials within 15 calendar days for findings from epidemiological
studies, pooled analyses of multiple studies, or other clinical studies
that suggest a significant risk in humans exposed to the drug.
Section 312.32(c)(1)(iii) specifies the requirements for reporting
to FDA in an IND safety report potential serious risks from clinical
trials within 15 calendar days for findings from in vitro testing that
suggest a significant risk to humans.
Section 312.32(c)(1)(iv) requires reporting to FDA in an IND safety
report within 15 calendar days of any clinically important increase in
the rate of occurrence of serious suspected adverse reactions over that
listed in the protocol or investigator brochure.
The rulemaking also included new information collection under the
PRA by requiring safety reporting for bioavailability and
bioequivalence studies (21 CFR 320.31(d)).
In tables 1 and 2 of this document, the estimates for ``No. of
Respondents,'' ``No. of Responses per Respondent,'' and ``Total Annual
Responses'' were obtained from the Center for Drug Evaluation and
Research (CDER) and the Center for Biologics Evaluation and Research
(CBER) reports and data management systems for submissions received in
2013, 2014, and 2015, and from other sources familiar with the number
of submissions received under the noted 21 CFR section. The estimates
for ``Hours per Response'' are unchanged based on information from CDER
and CBER individuals familiar with the burden associated with these
reports and from prior estimates received from the pharmaceutical
industry. FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden--(CDER) \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
320.31(d) Bioavailability and 13 15 195 14 2,730
Bioequivalence Safety Reports..
312.32(c)(1)(ii) and (c)(1)(iii) 100 6 600 12 7,200
IND Safety Reports.............
312.32(c)(1)(iv) IND Safety 10 1 10 12 120
Reports........................
---------------
Total (CDER)................ .............. .............. .............. .............. 10,050
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 14862]]
Table 2--Estimated Annual Reporting Burden--(CBER) \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
320.31(d) Bioavailability and 1 1 1 14 14
Bioequivalence Safety Reports..
312.32(c)(1)(ii) and (c)(1)(iii) 137 4 548 12 6,576
IND Safety Reports.............
312.32(c)(1)(iv) IND Safety 5 1.4 7 12 84
Reports........................
---------------
Total (CBER)................ .............. .............. .............. .............. 6,674
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: March 14, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-06128 Filed 3-17-16; 8:45 am]
BILLING CODE 4164-01-P